Annual FCF
-$99.91 M
-$19.73 M-24.60%
31 December 2023
Summary:
Spyre Therapeutics annual free cash flow is currently -$99.91 million, with the most recent change of -$19.73 million (-24.60%) on 31 December 2023. During the last 3 years, it has fallen by -$45.62 million (-84.03%). SYRE annual FCF is now -1229.30% below its all-time high of -$7.52 million, reached on 01 December 2014.SYRE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$29.42 M
+$32.83 M+52.74%
30 September 2024
Summary:
Spyre Therapeutics quarterly free cash flow is currently -$29.42 million, with the most recent change of +$32.83 million (+52.74%) on 30 September 2024. Over the past year, it has increased by +$5.18 million (+14.96%). SYRE quarterly FCF is now -1533.77% below its all-time high of $2.05 million, reached on 01 June 2021.SYRE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$151.25 M
+$5.18 M+3.31%
30 September 2024
Summary:
Spyre Therapeutics TTM free cash flow is currently -$151.25 million, with the most recent change of +$5.18 million (+3.31%) on 30 September 2024. Over the past year, it has dropped by -$64.23 million (-73.82%). SYRE TTM FCF is now -11037.48% below its all-time high of -$1.36 million, reached on 01 March 2014.SYRE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.6% | +15.0% | -73.8% |
| 3 y3 years | -84.0% | -52.7% | -178.6% |
| 5 y5 years | -48.7% | -68.4% | -125.1% |
SYRE Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -84.0% | at low | -95.2% | +52.7% | -178.6% | +3.3% |
| 5 y | 5 years | -84.0% | at low | -1533.8% | +52.7% | -184.6% | +3.3% |
| alltime | all time | -1229.3% | at low | -1533.8% | +52.7% | <-9999.0% | +3.3% |
Spyre Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$29.42 M(-52.7%) | -$151.25 M(-3.3%) |
| June 2024 | - | -$62.25 M(+118.1%) | -$156.42 M(+41.2%) |
| Mar 2024 | - | -$28.54 M(-8.0%) | -$110.82 M(+10.9%) |
| Dec 2023 | -$99.91 M(+24.6%) | -$31.04 M(-10.3%) | -$99.91 M(+14.8%) |
| Sept 2023 | - | -$34.60 M(+107.9%) | -$87.01 M(+28.9%) |
| June 2023 | - | -$16.64 M(-5.6%) | -$67.49 M(-5.6%) |
| Mar 2023 | - | -$17.63 M(-2.8%) | -$71.52 M(-10.8%) |
| Dec 2022 | -$80.18 M(+47.7%) | - | - |
| Dec 2022 | - | -$18.14 M(+20.4%) | -$80.18 M(-1.4%) |
| Sept 2022 | - | -$15.07 M(-27.1%) | -$81.31 M(-2.4%) |
| June 2022 | - | -$20.67 M(-21.4%) | -$83.33 M(+37.5%) |
| Mar 2022 | - | -$26.30 M(+36.5%) | -$60.61 M(+11.6%) |
| Dec 2021 | -$54.29 M(-32.2%) | -$19.27 M(+12.7%) | -$54.29 M(+2.1%) |
| Sept 2021 | - | -$17.09 M(-933.0%) | -$53.15 M(-1.9%) |
| June 2021 | - | $2.05 M(-110.3%) | -$54.16 M(-29.6%) |
| Mar 2021 | - | -$19.98 M(+10.2%) | -$76.95 M(-3.9%) |
| Dec 2020 | -$80.06 M(+19.2%) | -$18.13 M(+0.2%) | -$80.06 M(+0.8%) |
| Sept 2020 | - | -$18.10 M(-12.7%) | -$79.39 M(+1.0%) |
| June 2020 | - | -$20.74 M(-10.2%) | -$78.64 M(+5.8%) |
| Mar 2020 | - | -$23.08 M(+32.1%) | -$74.34 M(+10.7%) |
| Dec 2019 | -$67.18 M | -$17.47 M(+0.7%) | -$67.18 M(+17.6%) |
| Sept 2019 | - | -$17.35 M(+5.5%) | -$57.12 M(+18.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$16.44 M(+3.2%) | -$48.37 M(+17.9%) |
| Mar 2019 | - | -$15.93 M(+115.1%) | -$41.01 M(+25.7%) |
| Dec 2018 | -$32.62 M(+29.3%) | -$7.40 M(-13.9%) | -$32.62 M(+4.3%) |
| Sept 2018 | - | -$8.60 M(-5.2%) | -$31.28 M(+3.7%) |
| June 2018 | - | -$9.08 M(+20.6%) | -$30.15 M(+11.4%) |
| Mar 2018 | - | -$7.53 M(+24.2%) | -$27.06 M(+7.2%) |
| Dec 2017 | -$25.23 M(+32.4%) | -$6.06 M(-18.9%) | -$25.23 M(+6.7%) |
| Sept 2017 | - | -$7.48 M(+24.9%) | -$23.65 M(+7.3%) |
| June 2017 | - | -$5.99 M(+5.0%) | -$22.03 M(+6.1%) |
| Mar 2017 | - | -$5.70 M(+27.4%) | -$20.77 M(+9.0%) |
| Dec 2016 | -$19.05 M(+70.3%) | -$4.48 M(-23.7%) | -$19.05 M(+23.3%) |
| Sept 2016 | - | -$5.87 M(+24.2%) | -$15.45 M(+14.2%) |
| June 2016 | - | -$4.72 M(+18.3%) | -$13.53 M(+6.6%) |
| Mar 2016 | - | -$3.99 M(+357.0%) | -$12.69 M(+13.4%) |
| Dec 2015 | -$11.19 M(+48.9%) | -$873.00 K(-77.9%) | -$11.19 M(-16.4%) |
| Sept 2015 | - | -$3.94 M(+1.7%) | -$13.38 M(+18.3%) |
| June 2015 | - | -$3.88 M(+55.6%) | -$11.31 M(+30.8%) |
| Mar 2015 | - | -$2.49 M(-18.7%) | -$8.65 M(+15.1%) |
| Dec 2014 | -$7.52 M | -$3.07 M(+63.5%) | -$7.52 M(+68.9%) |
| Sept 2014 | - | -$1.88 M(+54.1%) | -$4.45 M(+72.8%) |
| June 2014 | - | -$1.22 M(-10.4%) | -$2.58 M(+89.6%) |
| Mar 2014 | - | -$1.36 M | -$1.36 M |
FAQ
- What is Spyre Therapeutics annual free cash flow?
- What is the all time high annual FCF for Spyre Therapeutics?
- What is Spyre Therapeutics annual FCF year-on-year change?
- What is Spyre Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly FCF year-on-year change?
- What is Spyre Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Spyre Therapeutics?
- What is Spyre Therapeutics TTM FCF year-on-year change?
What is Spyre Therapeutics annual free cash flow?
The current annual FCF of SYRE is -$99.91 M
What is the all time high annual FCF for Spyre Therapeutics?
Spyre Therapeutics all-time high annual free cash flow is -$7.52 M
What is Spyre Therapeutics annual FCF year-on-year change?
Over the past year, SYRE annual free cash flow has changed by -$19.73 M (-24.60%)
What is Spyre Therapeutics quarterly free cash flow?
The current quarterly FCF of SYRE is -$29.42 M
What is the all time high quarterly FCF for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly free cash flow is $2.05 M
What is Spyre Therapeutics quarterly FCF year-on-year change?
Over the past year, SYRE quarterly free cash flow has changed by +$5.18 M (+14.96%)
What is Spyre Therapeutics TTM free cash flow?
The current TTM FCF of SYRE is -$151.25 M
What is the all time high TTM FCF for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM free cash flow is -$1.36 M
What is Spyre Therapeutics TTM FCF year-on-year change?
Over the past year, SYRE TTM free cash flow has changed by -$64.23 M (-73.82%)